Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1613046 | 0.92 | KMT2A (0.49) | CAPN1P2RX7KMT2AKDM4EMEN1 | |
| SCHEMBL289326 | 0.92 | KMT2A (0.49) | CAPN1P2RX7KMT2AKDM4EMEN1 | |
| SCHEMBL288455 | 0.87 | CAPN1 (0.63) | CAPN1P2RX7HCRTR1HCRTR2 | |
| SCHEMBL1612123 | 0.87 | CAPN1 (0.63) | CAPN1P2RX7HCRTR1HCRTR2 | |
| SCHEMBL24434876 | 0.85 | KMT2A (0.47) | CAPN1P2RX7HCRTR1HCRTR2KMT2A | |
| SCHEMBL29127664 | 0.82 | SIGMAR1 (0.42) | KMT2AKDM4EMEN1ALDH1A1CYP19A1 | |
| SCHEMBL14319043 | 0.79 | MEN1 (0.42) | HCRTR1HCRTR2KMT2AKDM4EMEN1 | |
| SCHEMBL28820300 | 0.79 | CAPN1 (0.64) | CAPN1P2RX7HCRTR1HCRTR2CYP2C9 | |
| SCHEMBL14285586 | 0.79 | MEN1 (0.42) | HCRTR1HCRTR2KMT2AKDM4EMEN1 | |
| SCHEMBL288651 | 0.78 | P2RX7 (0.56) | CAPN1P2RX7HCRTR1HCRTR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | CAPN1 1773/4885P2RX7 3961/4885HCRTR1 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.